TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25452591

Group type: EXPERIMENTAL
Intervention: High vaginal loads of Atopobium vaginae and Gardnerella vaginalis
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: High vaginal load of Atopobium vaginae
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: A. vaginae levels ≥10(8) copies/mL
Number of subjects: 813
Study: 25452614

Group type: EXPERIMENTAL
Intervention: aNK-DLI (IL-15/4-1BBL-activated NK cells)
Number of subjects: 9
Study: 25452708

Group type: EXPERIMENTAL
Intervention: GnRH antagonist 0.25 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: recLH (Luveris, 150 IU/day) added to 'over-suppressed' patients
Number of subjects: 50
Study: 25452859

Group type: EXPERIMENTAL
Intervention: Retinopathy
Number of subjects: 4038

Group type: COMPARATOR
Intervention: No retinopathy
Number of subjects: 4038
Study: 25452867

Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D3
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 25 μg vitamin D3
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 25452874

Group type: EXPERIMENTAL
Intervention: Medtronic Sentrino continuous glucose management (CGM) system
Number of subjects: 21
Study: 25453541

Group type: EXPERIMENTAL
Intervention: High glycemic load diet
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: High glycemic index diet (in participants with BMI ≥ 25)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: High glycemic index diet (in participants with BMI < 25)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Adjusted for BMI, alcohol consumption, and total energy intake
Number of subjects: 306
Study: 25453718

Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve implantation
Number of subjects: 64
Study: 25453876

Group type: EXPERIMENTAL
Intervention: 25-cm Gore Viabahn Endoprosthesis
Number of subjects: 71
Study: 25453890

Group type: EXPERIMENTAL
Intervention: PTFE-covered stent-grafts
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Polyester covered stent-grafts
Number of subjects: 118
Study: 25454012

Group type: EXPERIMENTAL
Intervention: Asthma identification and medication administration forms
Number of subjects: 0
Study: 25455511

Group type: EXPERIMENTAL
Intervention: Steady-State Plasma Glucose (SSPG)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Steady-State Plasma Glucose (SSPG) in adults <45 years
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) in adults ≥45 years
Number of subjects: 39
Study: 25456091

Group type: EXPERIMENTAL
Intervention: Training plus organizational linkage intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Training alone
Number of subjects: 20
Study: 25456362

Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg or 30 mg orally once daily) until progressive disease, unacceptable toxicity, or patient withdrawal
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg or 30 mg orally once daily)
Number of subjects: 89
Study: 25456368

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (8 mg/kg intravenously every 3 weeks then 6 mg/kg intravenously every 3 weeks for the second course)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (6 mg/kg intravenously every 3 weeks) plus bevacizumab (15 mg/kg intravenously every 3 weeks; group A)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (6 mg/kg intravenously every 3 weeks; group B)
Number of subjects: 142
Study: 25456369

Group type: EXPERIMENTAL
Intervention: Oral ixazomib (2.97 mg/m2) plus lenalidomide 25 mg and dexamethasone 40 mg for up to 12 cycles, followed by maintenance therapy with ixazomib alone.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oral ixazomib (3.95 mg/m2) in phase 1.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oral ixazomib (2.23 mg/m2, converted to 4.0 mg fixed dose) in phase 2.
Number of subjects: 65
Study: 25456414

Group type: EXPERIMENTAL
Intervention: Cobalt-chromium thin strut bare metal stent with passive coating
Number of subjects: 1016
Study: 25456692

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 25456759

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with SAPIEN 3 valve
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nontransfemoral alternative access
Number of subjects: 150
Study: 25457053

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffold (BRS) implantation
Number of subjects: 40
Study: 25457458

Group type: EXPERIMENTAL
Intervention: Multibranched endovascular aneurysm repair
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Baseline glomerular filtration rate <30 mL/min/1.73 m(2)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Fluoroscopy time >190 minutes
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sustained hypotension
Number of subjects: 116
Study: 25457633

Group type: EXPERIMENTAL
Intervention: Dovitinib 500 mg once daily on a 5-days-on/2-days-off schedule
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 44
Study: 25458435

Group type: EXPERIMENTAL
Intervention: Endurant stent graft
Number of subjects: 1263
Study: 25458728

Group type: EXPERIMENTAL
Intervention: Subretinal transplantation of hESC-derived retinal pigment epithelium (50,000, 100,000, and 150,000 cells)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subretinal transplantation of hESC-derived retinal pigment epithelium
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated fellow eyes
Number of subjects: 18
Study: 25458735

Group type: EXPERIMENTAL
Intervention: FXIII concentrate (human) 40 IU kg(-1) on Days 0, 28, and 56
Number of subjects: 14
Study: 25459038

Group type: EXPERIMENTAL
Intervention: Melody transcatheter pulmonary valve (TPV) implantation
Number of subjects: 100
Study: 25459109

Group type: EXPERIMENTAL
Intervention: (111)In-BzDTPA-pertuzumab (2.5MBq; 2μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (111)In-BzDTPA-pertuzumab (1.0MBq, 20μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control mice injected with unlabeled BzDTPA-pertuzumab (20μg) or Sodium Chloride Injection USP
Number of subjects: 0
Study: 25459243

Group type: EXPERIMENTAL
Intervention: Cognitive impairment assessment using the MUSIC score (mean score 20.6 ± 5.4)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lesion volumes (LV) and disability severity
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Interference test from MUSIC subtests
Number of subjects: 78
Study: 25460357

Group type: EXPERIMENTAL
Intervention: Unrelated cord blood transplantation (UCBT) using reduced-intensity conditioning (RIC) consisting of total body irradiation (2 Gy), cyclophosphamide (50 mg/kg), and fludarabine (200 mg/m(2)).
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Unrelated cord blood transplantation (UCBT) using reduced-intensity conditioning (RIC).
Number of subjects: 79
Study: 25461210

Group type: EXPERIMENTAL
Intervention: Lacosamide (100-800 mg/day)
Number of subjects: 370
Study: 25461221

Group type: EXPERIMENTAL
Intervention: Higher perceived epilepsy-related stigma
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Stigma on adherence
Number of subjects: 140
Study: 25461821

Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cytokines and chemokines
Number of subjects: 36
Study: 25462205

Group type: EXPERIMENTAL
Intervention: Vinorelbine 25mg/m(2) followed by gemcitabine 1000mg/m(2) administered intravenously on days 1 and 8 every 3 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Vinorelbine and gemcitabine combination chemotherapy
Number of subjects: 44
Study: 25464386

Group type: EXPERIMENTAL
Intervention: TP53 mutations
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: CDKN2A deletions
Number of subjects: 112

Group type: COMPARATOR
Intervention: Normal TP53/CDKN2A gene status
Number of subjects: 112
Study: 25464481

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires on perceived health status (12-item Short-form Health Survey & EuroQOL-5D)
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires on psychological functioning (Hospital Anxiety and Depression Scale)
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires on health behaviors (Health-Behavior Scale-Congenital Heart Disease)
Number of subjects: 3500

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires on quality of life (Linear Analog Scale & Satisfaction With Life Scale)
Number of subjects: 3500
Study: 25464836

Group type: EXPERIMENTAL
Intervention: Behavioral Activation therapy (BA-W) for 12 weeks
Number of subjects: 16
Study: 25465231

Group type: EXPERIMENTAL
Intervention: High-dose treatment arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major molecular remission
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25465273

Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with T1DM
Number of subjects: 3048

Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with T2DM
Number of subjects: 3048

Group type: EXPERIMENTAL
Intervention: Retrospective survey for T1DM
Number of subjects: 3048

Group type: EXPERIMENTAL
Intervention: Retrospective survey for T2DM
Number of subjects: 3048

Group type: EXPERIMENTAL
Intervention: Severe hypoglycaemia events in T1DM
Number of subjects: 3048

Group type: EXPERIMENTAL
Intervention: Severe hypoglycaemia events in T2DM
Number of subjects: 3048

Group type: EXPERIMENTAL
Intervention: Physician-reported severe hypoglycaemia in T1DM
Number of subjects: 3048

Group type: EXPERIMENTAL
Intervention: Physician-reported severe hypoglycaemia in T2DM
Number of subjects: 3048
Study: 25465496

Group type: EXPERIMENTAL
Intervention: Right ventricular pacing from the apex
Number of subjects: 408

Group type: COMPARATOR
Intervention: Right ventricular pacing from the septal site
Number of subjects: 408
Study: 25466258

Group type: EXPERIMENTAL
Intervention: (18)FDG-PET in patients with PNES
Number of subjects: 16

Group type: COMPARATOR
Intervention: (18)FDG-PET in healthy controls
Number of subjects: 16
Study: 25466314

Group type: EXPERIMENTAL
Intervention: Qualitative interviews conducted at 3, 6, 12, and 24 months after ICU discharge
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Interventions designed to improve family outcomes after critical illness
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Early intervention and support
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ongoing family-centered follow-up programs
Number of subjects: 12
Study: 25466382

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily
Number of subjects: 37
Study: 25466513

Group type: EXPERIMENTAL
Intervention: Overall dementia prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vascular dementia (VD) prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive impairment prevalence (CIND)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CIND-other prevalence
Number of subjects: 0
Study: 25466521

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 1921260
Study: 25466757

Group type: EXPERIMENTAL
Intervention: HPV DNA detection
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Single HPV type infection
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Multiple HPV type infection
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Unidentifiable HPV type infection
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Most prevalent HPV types
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Co-infection with other HR-HPV types
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: HPV awareness
Number of subjects: 571
Study: 25466778

Group type: EXPERIMENTAL
Intervention: MVA85A vaccination
Number of subjects: 0
Study: 25468293

Group type: EXPERIMENTAL
Intervention: Bedside simulation-based training for CVL dressing change and maintenance bundle with intermittent training refreshers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard CVL bundle training process
Number of subjects: 0
Study: 25468505

Group type: EXPERIMENTAL
Intervention: ALTAIR software platform for automatic image analysis of retinal vessel calibre
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: TOPCON TRCNW200 non-mydriatic retinal camera
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Intraobserver and interobserver reliability assessments
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Concurrent validity assessments
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Measurements of carotid intima-media thickness, pulse wave velocity, cardio-ankle vascular index, digital ECG, microalbuminuria, and glomerular filtration
Number of subjects: 386
Study: 25468512

Group type: EXPERIMENTAL
Intervention: Lacosamide 300 mg/day
Number of subjects: 27
Study: 25468655

Group type: EXPERIMENTAL
Intervention: Presence of preamyloid oligomers (PAOs) in atrial tissue
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PAO burden quantified by mean green/red ratio
Number of subjects: 92
Study: 25469734

Group type: EXPERIMENTAL
Intervention: Absorb Bioresorbable Vascular Scaffold System (Absorb BVS)
Number of subjects: 1000
Study: 25469987

Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index
Number of subjects: 181764

Group type: EXPERIMENTAL
Intervention: Prior costs
Number of subjects: 181764

Group type: EXPERIMENTAL
Intervention: Diagnostic Cost Group (DCG)
Number of subjects: 181764

Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index, prior costs, and DCG
Number of subjects: 181764
Study: 25470338

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 36
Study: 25470818

Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir (IVZ) 600 mg twice daily for five days
Number of subjects: 21
Study: 25471062

Group type: EXPERIMENTAL
Intervention: Early Detection (ED) implemented by the First-episode Services (FES) STEP in southern Connecticut
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual detection efforts at the comparable FES PREP(R) serving the greater Boston metropolitan area
Number of subjects: 0
Study: 25472823

Group type: EXPERIMENTAL
Intervention: Copeptin levels before examination
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Serum cortisol levels before examination
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Salivary cortisol levels before examination
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Copeptin levels after examination
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cortisol levels and academic performance
Number of subjects: 25
Study: 25472874

Group type: EXPERIMENTAL
Intervention: VWF:Ag levels in ACS patients
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: VWF:Ag levels in SAP patients
Number of subjects: 581
Study: 25473029

Group type: EXPERIMENTAL
Intervention: Anidulafungin 200 mg every 48 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anidulafungin 300 mg every 72 h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Licensed regimen
Number of subjects: 20
Study: 25473804

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: NGAL
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP and NGAL
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combination of BNP and NGAL
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: In-hospital length of stay (LOS)
Number of subjects: 101
Study: 25474185

Group type: EXPERIMENTAL
Intervention: Exhaled VOCs
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Gene expression of toll-like receptor 4, catalase, and tumor necrosis factor-α
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Combined model with VOCs, gene expression, and API
Number of subjects: 202

Group type: COMPARATOR
Intervention: Biomarkers in exhaled breath condensate and airway resistance (pre- and post-bronchodilator)
Number of subjects: 202
Study: 25474373

Group type: EXPERIMENTAL
Intervention: CAT (COPD Assessment Test)
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: mMRC (Modified Medical Research Council)
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Assessment according to LLN (Lower Limit of Normal)
Number of subjects: 1465
Study: 25475068

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccines prepared by the adherence method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dendritic cell vaccines prepared by the antibody-selected CD14+ method
Number of subjects: 0
Study: 25475080

Group type: EXPERIMENTAL
Intervention: EBV-positive DLBCL in young adults
Number of subjects: 571

Group type: COMPARATOR
Intervention: EBV-positive DLBCL in elderly group
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: EBV-positive DLBCL in young group
Number of subjects: 571
Study: 25475207

Group type: EXPERIMENTAL
Intervention: Migraine group (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n=25)
Number of subjects: 50
Study: 25475246

Group type: EXPERIMENTAL
Intervention: Emergency department care
Number of subjects: 5632
Study: 25475413

Group type: EXPERIMENTAL
Intervention: THC/CBD oromucosal spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25475601

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily for 5 days followed by warfarin loading dose of 5 or 10 mg once daily for 2-4 days (co-administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin alone (monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 0
Study: 25476715

Group type: EXPERIMENTAL
Intervention: Serum bilirubin levels >1.1 mg/dL in patients with no appendiceal inflammation (14%) vs any appendicitis (36%)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Serum bilirubin levels >1.1 mg/dL in patients with non-perforated appendicitis (48%) vs perforated appendicitis
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Positive likelihood ratio for elevated bilirubin in discriminating no appendiceal inflammation vs any appendicitis
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Positive likelihood ratio for elevated bilirubin in discriminating non-perforated appendicitis vs perforated appendicitis
Number of subjects: 493
Study: 25477010

Group type: EXPERIMENTAL
Intervention: Gemcitabine/cisplatin/S-1 combination chemotherapy
Number of subjects: 50
Study: 25478013

Group type: EXPERIMENTAL
Intervention: Ankle fracture patients
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Unimalleolar fracture group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bimalleolar fracture group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 25478017

Group type: EXPERIMENTAL
Intervention: AADvac1 tau peptide vaccine
Number of subjects: 0
Study: 25478028

Group type: EXPERIMENTAL
Intervention: Therapeutic educational programme
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 170
Study: 25478141

Group type: EXPERIMENTAL
Intervention: 12 weeks SMT + SRE
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 36 weeks SMT + SRE
Number of subjects: 200
Study: 25478142

Group type: EXPERIMENTAL
Intervention: Active chiropractic treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham chiropractic treatment
Number of subjects: 26
Study: 25478169

Group type: EXPERIMENTAL
Intervention: Therapeutic interventions for IPF
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Registry data collection
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Comparative analysis
Number of subjects: 500
Study: 25478181

Group type: EXPERIMENTAL
Intervention: Testing for methylated p16 in sputum
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Educational presentation regarding p16 function
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-risk test results
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High-risk test results
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Smoking cessation rates
Number of subjects: 35
Study: 25478585

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection
Number of subjects: 14
Study: 25478681

Group type: EXPERIMENTAL
Intervention: Initial tidal volume of 1 ml/kg PBW increase
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Subsequent tidal volume of 1 ml/kg PBW increase
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Receiving 10 ml/kg PBW for 8 days
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Receiving 8 ml/kg PBW for 8 days
Number of subjects: 482
Study: 25479117

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen
Number of subjects: 101

Group type: COMPARATOR
Intervention: Nonrebreathing bag reservoir facemask
Number of subjects: 101
Study: 25479121

Group type: EXPERIMENTAL
Intervention: (18)F-FDG hrPET
Number of subjects: 10

Group type: COMPARATOR
Intervention: MRI (SE sequence)
Number of subjects: 10

Group type: COMPARATOR
Intervention: MRI (SPGR sequence)
Number of subjects: 10
Study: 25479633

Group type: EXPERIMENTAL
Intervention: interRAI Palliative Care instrument (interRAI PC)
Number of subjects: 15
Study: 25480497

Group type: EXPERIMENTAL
Intervention: Age-adjusted multi-agent immunochemotherapy regimen with temozolomide maintenance
Number of subjects: 66
Study: 25480498

Group type: EXPERIMENTAL
Intervention: Serum survivin levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor levels
Number of subjects: 0
Study: 25480772

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Processed NIRS information for monitoring cerebral autoregulation and tissue oxygenation
Number of subjects: 0
Study: 25481376

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) administered within 15 min of mifepristone administration
Number of subjects: 20